Karen uses this session to analyze payer perspectives in genetic counseling. She describes the process involved with genetic counseling and the role of the counselor. She notes that the path to becoming a genetic counselor can often be more rigorous than in other specialties. Ms Lewis also discusses the surge of interest that genetic counseling has seen in recent years.
Karen uses this session to analyze payer perspectives in genetic counseling. She describes the process involved with genetic counseling and the role of the counselor. She notes that the path to becoming a genetic counselor can often be more rigorous than in other specialties. Ms Lewis also discusses the surge of interest that genetic counseling has seen in recent years.
“Most of you are very well aware of potential personalized medicine, looking at various tumor markers and knowing well, an individual that has this mutation is not going to respond well to treatment A and therefore, we need to try treatment B instead. Individuals want to know this information,” she says. “It’s everywhere. I don’t know a TV program out there that—in some way, shape, or form—hasn’t used genetics or testing or something in their plot line.”
However, she warns that some clinics may only use genetic counseling as a path to profit. Another issue for some may be access, as there are only about 3000 board-certified genetic counselors in the United States, and they are concentrated in large metropolitan areas. She also suggests that genetic testing must be given appropriately to patients.
“I think the benefits of utilization of genetic counseling are multiple, but one of the biggest benefits is avoiding inappropriate testing. Not avoiding testing in general, just avoiding the wrong test. So, what we want to do is make sure that the right tests are being given to the right patients,” Ms Lewis says.
Overall, comprehensive policies and genetic testing have potential to improve care, improve cost-effectiveness, and improve outcomes.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More